Opinion|Videos|May 30, 2024
Leveraging Neuroimaging Modalities and Guidelines in Glioblastoma
Author(s)Nathalie Albert, MD , Matthias Preusser, MD
Medical experts discuss the use of various neuroimaging techniques, such as MRIs, CT scans, and PET scans, emphasizing that due to limitations of MRI it is frequently combined with other modalities to obtain more comprehensive information.
Advertisement
Episodes in this series
Advertisement
Related to this article
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.
Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5